RecruitingNot ApplicableNCT07630402

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Pilot Study for Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer


Sponsor

University of Rochester

Enrollment

20 participants

Start Date

Nov 17, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 79 Years

Inclusion Criteria4

  • Female sex, age 18-79 years.
  • Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
  • Baseline LVEF ≥ 55 % by 2-D echocardiography.
  • Ability to provide informed consent.

Exclusion Criteria5

  • Prior HF, myocardial infarction, or cardiomyopathy.
  • Atrial fibrillation or significant valvular heart disease.
  • Cumulative anthracycline dose ≥ 250 mg/m².
  • Pregnancy or lactation.
  • Inability to comply with study procedures.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREEchocardiogram

12-lead echocardiogram


Locations(1)

Wilmot Cancer Center

Rochester, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07630402


Related Trials